ストックスクリーナーアプリを入手
6.165
2.41%
0.155
前日終値:
$6.01
開ける：
$6.095
24時間の取引高:
2.63M
Relative Volume:
0.58
時価総額：
$1.03B
収益：
$847.25M
当期純損益:
$-284.86M
株価収益率:
-2.6921
EPS:
-2.29
ネットキャッシュフロー:
$-112.35M
1週間 パフォーマンス:
-3.68%
1か月 パフォーマンス:
-19.01%
6か月 パフォーマンス:
-39.18%
1年 パフォーマンス:
+51.23%
1日の値動き範囲:
$6.04
$6.25
1週間の範囲:
$5.81
$6.38
52週間の値動き範囲:
$3.90
$23.86
Novavax Inc Stock (NVAX) Company Profile
NVAX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
6.165 | 1.03B | 847.25M | -284.86M | -112.35M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.29 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
582.31 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.81 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
253.56 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-28 | 開始されました | BTIG Research | Buy |
| 2024-07-30 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2024-05-10 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-05-10 | アップグレード | JP Morgan | Underweight → Neutral |
| 2023-08-09 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | 繰り返されました | B. Riley Securities | Buy |
| 2022-12-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2022-12-02 | 開始されました | Jefferies | Hold |
| 2022-09-22 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-05-20 | 開始されました | BofA Securities | Underperform |
| 2022-02-23 | 繰り返されました | B. Riley Securities | Buy |
| 2022-02-22 | 再開されました | Jefferies | Buy |
| 2022-01-21 | 開始されました | Cowen | Outperform |
| 2021-05-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-12-14 | 開始されました | Jefferies | Buy |
| 2020-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-05 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-08-05 | ダウングレード | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-08 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | 繰り返されました | B. Riley FBR | Buy |
| 2020-06-29 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-05 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-05-28 | 繰り返されました | B. Riley FBR | Buy |
| 2020-05-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-11-27 | 再開されました | B. Riley FBR | Buy |
| 2019-08-14 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-02-28 | ダウングレード | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | 開始されました | Ladenburg Thalmann | Buy |
| 2018-12-11 | 開始されました | Oppenheimer | Outperform |
| 2018-11-26 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | アップグレード | JP Morgan | Underweight → Overweight |
| 2018-03-29 | アップグレード | Seaport Global Securities | Neutral → Buy |
すべてを表示
Novavax Inc (NVAX) 最新ニュース
Learn to Evaluate (NVAX) using the Charts - news.stocktradersdaily.com
Why the Market Dipped But Novavax (NVAX) Gained Today - Yahoo Finance
Preventive Vaccines Market Forecast 2025-2032- Growth - openPR.com
Novavax (NVAX) Shows Promising Vaccine Results Amid Market Stability - GuruFocus
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Gaithersburg-Based Novavax’s COVID-19 Vaccine Shows Lower Side Effects Than Pfizer-BioNTech - The MoCo Show -
Lobbying Update: $50,000 of NOVAVAX INC. lobbying was just disclosed - Nasdaq
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Novavax (NasdaqGS:NVAX) Study Shows Reduced Symptoms With New COVID-19 Vaccine Formula - Yahoo Finance
At ACIP hearing, CDC says it's 'scraping' to respond to measles outbreak; FDA comments on Novavax halt - Endpoints News
Novavax vaccine shows fewer side effects in study By Investing.com - Investing.com South Africa
Here's Why Novavax (NVAX) Fell More Than Broader Market - Yahoo Finance
Novavax Inc (NVAX) Stock Price, Trades & News - GuruFocus
Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study - Benzinga
US CDC advisers begin review of vaccine guidelines after months-long delay - marketscreener.com
Novavax vaccine shows fewer side effects in study - Investing.com Australia
Novavax Says COVID-19 Vaccine Induces Fewer Symptoms Compared With Pfizer's Vaccine - marketscreener.com
Novavax (NVAX) COVID-19 Vaccine Shows Lower Reactogenicity in SH - GuruFocus
SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower - GuruFocus
Shield-Utah Study Shows Novavax's Covid-19 Vaccine Induces Lower Reactogenicity Symptoms Compared To Mrna - marketscreener.com
NVAX Stock Tanks as HHS Secretary Raises Concern Over COVID-19 Jab - MSN
SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA - The Herald Journal
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax (NVAX) Stock Plunges Amid Approval Delay - GuruFocus
Shares plunge after RFK Jr questions Novavax approach - The Pharma Letter
Novavax Retail Traders Rally In Defense After RFK Jr.'s COVID-19 Vaccine Skepticism Sends Stock Tumbling - MSN
Novavax (NVAX) Shares Plummet Amid Vaccine Effectiveness Concerns - GuruFocus
Novavax slides after RFK Jr. casts doubts about COVID vaccine - Yahoo Finance
Novavax (NVAX) Awaits FDA Decision Amid Vaccine Approval Delay | - GuruFocus
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Novavax: Regulatory Uncertainty Creates Risk And Opportunity For Beaten-Down Vaccine Developer - Seeking Alpha
Novavax (NVAX) Faces Setback Amid COVID Vaccine Approval Delay - GuruFocus
Kennedy’s Comments On Novavax Delay Scientifically, Legally Inaccurate, Experts Say - insights.citeline.com
Update on Status of Novavax's COVID-19 Vaccine BLA - marketscreener.com
Novavax shares tumble after U.S. health secretary raises concerns over COVID shot's efficacy - Reuters
Novavax shares tumble after U.S. health secretary raises concerns over COVID shot’s efficacy - KFGO
Nike, Disney, Novavax: Trending Tickers - Yahoo Finance
Vaccine Makers Fall After RFK Jr. Says Some Shots Don’t Work - MSN
Novavax (NVAX) Stock Target Lowered Amidst Vaccine Approval Conc - GuruFocus
Novavax (NVAX) Shares Plunge After RFK Jr. Questions Its Covid Vaccine Efficacy - Bloomberg.com
Sector Update: Health Care Stocks Drop Thursday Afternoon - TradingView
BofA cuts Novavax stock price target to $10 from $12 - Investing.com
Novavax & RFK Jr., Costco sales, Lovesac earnings: Market Minute - Yahoo Finance
Novavax tumbles as Kennedy raises questions over COVID vaccine - TradingView
Novavax Shares Fall After RFK Jr. Questions Covid-19 Vaccine - marketscreener.com
Novavax (NVAX) Faces Stock Drop Amid FDA Vaccine Approval Delay - GuruFocus
Novavax Shares Plunge After RFK Jr. Questions Its Covid Vaccine - Bloomberg
Vaccine Makers Fall After RFK Jr. Says Some Shots Don’t Work (1) - Bloomberg Law News
Novavax in selloff after RFK Jr.’s comments on COVID vaccine - MSN
Japan approves Moderna COVID vaccine as booster, Novavax files for 1st approval - tuoitrenews.vn
Jazz (JAZZ) Moves 7.1% Higher: Will This Strength Last? - Yahoo Finance
Novavax Inc (NVAX) 財務データ
収益
当期純利益
現金流量
EPS
Novavax Inc (NVAX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Trizzino John | President and COO |
Mar 07 '25 |
Option Exercise |
0.00 |
28,890 |
0 |
82,015 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Mar 07 '25 |
Option Exercise |
0.00 |
12,223 |
0 |
75,155 |
| Trizzino John | President and COO |
Mar 01 '25 |
Option Exercise |
0.00 |
48,000 |
0 |
76,310 |
| Casey Mark J | EVP, Chief Legal Officer |
Mar 01 '25 |
Option Exercise |
0.00 |
4,000 |
0 |
33,187 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Mar 01 '25 |
Option Exercise |
0.00 |
58,667 |
0 |
91,269 |
| Jacobs John C | President and CEO |
Mar 01 '25 |
Option Exercise |
0.00 |
83,334 |
0 |
175,183 |
| O'Hara Elaine | EVP, Chief Strategy Officer |
Mar 01 '25 |
Option Exercise |
0.00 |
59,600 |
0 |
73,825 |
| Jacobs John C | President and CEO |
Jan 23 '25 |
Option Exercise |
0.00 |
83,196 |
0 |
130,722 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Dec 31 '24 |
Option Exercise |
0.00 |
35,000 |
0 |
49,508 |
| Rodgers Richard J | Director |
Oct 29 '24 |
Option Exercise |
0.00 |
3,800 |
0 |
14,270 |
1.75%
2.22%
大文字化:
|
ボリューム (24 時間):